Nigeria's former president Buhari dead at 82
Current President Bola Tinubu said in a statement that his predecessor died in London at about 4:30 pm (1530 GMT) "following a prolonged illness". He did not disclose the nature of the illness.
Buhari governed Nigeria with a strong hand as a military ruler in the 1980s before reinventing himself as a "converted democrat", serving two terms from 2015 to 2023.
"The family of the former president has announced the passing on of the former president, Muhammadu Buhari, this afternoon in a clinic in London," Garba Shehu, who served as Buhari's spokesman during his presidency, said in a post on social media.
Tinubu said he had spoken with Buhari's widow and ordered Vice President Kashim Shettima to go to England to accompany Buhari's body back to Nigeria.
He also ordered flags to fly at half-staff in honour of Buhari, whose tenure was dogged by health rumours.
His frequent visits for medical treatment during his presidency attracted criticism about the government's transparency over his illness and worries about leadership during some of his longer absences.
Although the nature of his ailment has never been made public, Buhari confessed in one of the trips that he had "never been so ill" and that he had received several blood transfusions.
Critics also said the visits highlighted the country's weak health system.
- 'A failure of leadership' -
Last week his aide Shehu launched a book, titled "According to the President: Lessons from a Presidential Spokesperson's Experience", in which according to local media he confessed to fabricating a 2017 story about rats' invasions at the presidential office, to shift Nigerians focus away from concerns over the leader's health.
Buhari had spent nearly three months away receiving treatment in Britain.
"When the surge in calls for explanation of why the president would be working from home, if truly he had recovered his health and fit for the office came, I said to the reporters that the office, which had been in disuse, needed renovation because rats may have eaten and damaged some cables," he wrote in the book, according to local media.
The rake-thin 82-year-old Muslim from Nigeria's far north made history as the first opposition candidate to defeat an incumbent leader at the ballot box in 2015.
His election victory in a country where re-election for the incumbent had been taken for granted was seen as a rare opportunity for Nigeria to change course.
But his time at the helm failed to halt the country's long-standing issues of graft and insecurity, while the oil giant was further dogged by economic woes.
Despite concerns about his fragile health, his economic policies, the extent of his claims about better security, as well as the targets of his campaign against graft, he secured a second term in 2019.
In a 2020 opinion piece for The New York Times, Nigerian writer Chimamanda Ngozi Adichie charged that his tenure in office had shown "a failure of leadership", writing that the "government of President Muhammadu Buhari has long been ineffectual, with a kind of wilful indifference."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
17 hours ago
- ABC News
Prince Harry cleared of bullying Sentebale boss Sophie Chandauku
Prince Harry has been cleared of bullying following a dispute with an African charity he founded. The charity, Sentebale, was at the centre of a boardroom dispute in late March and April when its chair, Sophie Chandauka, publicly accused Prince Harry of "bullying". Days earlier, Harry and co-founder Prince Seeiso of Lesotho announced they were resigning from the charity they established in 2006 after the trustees quit when Ms Chandauka refused their demand to step down. Harry launched the charity in honour of his mother, Princess Diana, to help young people with HIV and AIDS in Lesotho and later Botswana. After a months-long inquiry, the UK-based Charity Commission "found no evidence of widespread or systemic bullying or harassment, including misogyny or misogynoir at the charity". In its conclusions published on Wednesday, it "criticised all parties to the dispute for allowing it to play out publicly", saying it had "severely impacted the charity's reputation". The commission added there was "a lack of clarity in delegations" and this led to "mismanagement in the administration of the charity". It issued the charity with a plan to "address governance weaknesses". Prince Harry said in a statement an April that the events were "heartbreaking to witness, especially when such blatant lies hurt those who have invested decades in this shared goal". Ms Chandauka accused the Duke of Sussex of trying to force her out through "bullying [and] harassment" in an interview with Sky News. In one of her examples, Ms Chandauka criticised the prince for bringing a Netflix camera crew to the charity's polo fundraiser last year and for his wife Meghan's unplanned appearance at the event. The accusations were a fresh blow for the prince, who kept up only a handful of his private patronages, including with Sentebale after a dramatic split with the royal family in 2020, leaving the UK to live in North America with his wife and children. "Moving forward, I urge all parties not to lose sight of those who rely on the charity's services," the commission's chief executive David Holdsworth said. Prince Harry chose the name Sentebale as a tribute to Diana, who died in a Paris car crash in 1997 when the prince was just 12. It means "forget me not" in the Sesotho language and is also used to say goodbye. AFP

ABC News
18 hours ago
- ABC News
Rwanda becomes third African nation to take US deportees. What do we know about the secretive deals?
Rwanda has become the third African nation to enter into a deal with the Trump administration to accept migrants deported by the United States. The Rwandan government said on Tuesday it had agreed to accept up to 250 deportees from the US for resettlement but did not immediately give any more details, including when they would arrive or what Rwanda got, if anything, out of the deal. The US has already deported eight men it said were dangerous criminals who were in the US illegally to South Sudan and another five to Eswatini. The US State Department and the Department of Homeland Security have not responded to requests seeking more details on the deals in Africa. Here is what we know, and still do not know, about the largely secretive deals the US is striking. Rwanda's deal with the US comes after a contentious migrant agreement it reached with the UK in 2022 collapsed and was ruled unlawful by Britain's Supreme Court. That deal was meant to see people seeking asylum in the UK sent to Rwanda, where they would stay if their asylum applications were approved. The failed deal ultimately cost the UK around 700 million pounds ($1.4 billion) in public money, including more than 200 million pounds that it gave to Rwanda and did not get back. Rwanda said the deportees it would take from the US would be resettled there and given work training, health care and help with accommodation. The US sent eight men from South Sudan, Cuba, Laos, Mexico, Myanmar and Vietnam to South Sudan in East Africa in early July after their deportations were held up by a legal challenge. That led to them being kept for weeks in a converted shipping container at an American military base in nearby Djibouti. US officials said the men had been convicted of violent crimes in the US. When it took custody of them a month ago, the South Sudan government said it would ensure their "safety and wellbeing". It has since declined to give other details, including where the men are being held and what their fate might be. South Sudan has been wracked by conflict since it gained independence from Sudan in 2011 and is teetering on the edge of civil war again. Two weeks after the South Sudan deportations, the US announced that it had sent another five men — citizens of Vietnam, Jamaica, Cuba, Yemen and Laos — to the small kingdom of Eswatini in southern Africa. The US Department of Homeland Security said they were also violent criminals whose home countries had refused to take them back. Eswatini's government said the men would be held in solitary confinement until their repatriation, and later said that might take up to a year. A human rights lawyer in Eswatini has taken authorities to court, alleging the men are being denied legal representation while being held in a maximum-security prison, and questioning the legality of detaining them indefinitely when they have served their criminal sentences in the US. US authorities did not name the men or say if they had been deported straight from prison or detained in another way. Eswatini, which borders South Africa, is one of the world's last absolute monarchies. King Mswati III has ruled since he turned 18 in 1986. Authorities under him are accused of violently subduing pro-democracy movements in a country where political parties are effectively banned. Analysts say that African nations may be seeking a range of benefits from the Trump administration in return for taking deportees, including more favourable tariff rates, aid and other financial assistance, and even the easing of sanctions against some of their officials. AP

News.com.au
a day ago
- News.com.au
MoneyTalks: Summit Biotech Fund's three standout ASX healthcare stocks
MoneyTalks is Stockhead's drill down into what stocks investors are looking at right now. We tap our list of experts to hear what's hot, their top picks and what they're looking out for. Today we hear from Australia's Summit Biotech Fund manager Reece O'Connell. With experience trading through multiple economic and market cycles, Reece O'Connell has developed a long-term investment approach focused on preserving and growing capital. In a career that has taken him from Perth to London and back again, he has worked closely with high-net-worth and wholesale investors, tailoring strategies to meet their objectives while navigating changing market conditions. At Summit Biotech Fund (SBF) he aims to provide long-term capital growth by investing in a portfolio of life science companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices and equipment, medical data, information technology (e-health), and robotics. And in some good news for the fund, a rotation back into the healthcare sector appears to be gaining momentum with the S&P ASX 200 Health Care index rising 9.05% in July. "The healthcare sector has been the worst performing sector for two years and there's great positioning in quality healthcare names before the sector turns," he said. "We see these sector rotations every three to five years and I believe the ASX healthcare sector represents good value and plenty of upside in quality names with strong management." Here's three companies Summit Biotech Fund has invested in and why. Arovella Therapeutics (ASX:ALA) SBF is a major shareholder in Arovella, which is developing a next-generation cell therapy platform based on invariant Natural Killer T (iNKT) cells engineered with Chimeric Antigen Receptors (CARs) to target specific cancer antigens. Unlike traditional CAR-T therapies, Arovella's approach uses healthy donor cells to create off-the-shelf treatments, which reduces cost, complexity and time to treatment — the major issues currently faced by CAR-T companies. Arovella's lead candidate, ALA-101, targets CD19-positive blood cancers, and its pipeline encompasses therapy development for solid tumours such as gastric and pancreatic cancers. O'Connell reckons Arovella is in a hot area of cancer research. Nasdaq-listed MiNK Therapeutics recently soared following publication of a case report in the peer-reviewed Oncogene journal, detailing a patient with advanced, treatment-refractory testicular cancer who achieved complete remission after receiving its lead product iNKT Agentâ€'797, in combination with the immune checkpoint inhibitor nivolumab. "Arovella presents an opportunity in a rapidly growing sector, with a differentiated platform and strong early-stage clinical momentum," O'Connell said. "The company is the only ASX-listed biotech delving into CAR-iNKT therapies and one of only a handful globally." He said Arovella was well funded, finishing Q4 FY25 with cash of $20.9 million, which should fund the company through to completion of patient enrolment for its phase I clinical trial for ALA-101 n non-Hodgkin's lymphoma and leukaemia patients exhibiting the CD-19 biomarker – the target its CAR-iNKT cells recognise. The funding will also support the advancement of the company's solid tumour programs (CLDN18.2-CAR-iNKT targeting gastric cancer) and its armouring program (IL-12-TM). "ALA presents a highly compelling investment opportunity over the next six to 12 months, given the competitive landscape and the deals being struck for allogeneic assets and platforms," O'Connell added. SBF is a significant shareholder in Tryptamine, a clinical-stage biopharmaceutical company developing next-generation psychedelic medicines for neuropsychiatric conditions. Its lead program, TRP-8803, is a proprietary, IV-delivered formulation of psilocybin designed to provide more precise dosing and improved patient tolerability compared to oral psychedelic treatments. Phase 1b trials have already shown the drug to be safe and well tolerated in obese and non-obese participants. The company recently kicked off a world-first psilocin trial with TRP-8803 targeting Binge Eating Disorder (BED). The study, run in collaboration with Swinburne, will assess TRP-8803 when administered with psychotherapy with the goal to evaluate safety, feasibility and efficacy in adults diagnosed with BED. For O'Connell when analysing a biotech it as much about who is running the company as it is about the science. "One of the most important investment themes I always look for is a material monetary investment by directors in a company," he said. "Too many small ASX-listed companies have boards that aren't truly aligned with shareholders. "The number one way to be aligned is to have directors putting in their hard-earned cash like us. In this case, TYP ticks all the boxes.' He said directors, management,and major shareholders were collectively invested for more than $9m, with CEO Jason Carroll personally contributing more than $1 million. Carroll's 30-year career in big pharma includes two decades at Johnson & Johnson, where he led the strategy that doubled US sales of Remicade — a blockbuster IBD drug that ultimately reached US$10bn in annual global sales. O'Connell said other board members brought similar firepower. Executive director Chris Ntoumenopoulos was involved in the growth of Race Oncology (ASX:RAC) from $10m to north of $200m, founded former ASX-listed ResApp Health, which was acquired by Pfizer for ~$200m, and has helped double Island Pharmaceuticals' (ASX:ILA) value since joining its board. As part of the last raise experienced biotech investor Dr Daniel Tillett joined the Tryptamine board as a non-executive director and became a cornerstone investor. Tillet also cornerstoned a raise in Race Oncology in its early days and now leads it as CEO and managing director. Recent clinical progress provides Tryptamine with valuable proprietary data as its seek to advance the use of TRP-8803 in patient-specific indications. "With a differentiated psychedelic platform, directors heavily invested alongside shareholders, and multiple catalysts on the horizon, Tryptamine is emerging as one of the more compelling plays in the sector," O'Connell said. SBF also holds a strong position in NeuroScientific, which O'Connell said was positioning itself as a serious player in the fast-growing field of stem cell therapies for immune-mediated diseases, underpinned by its recently acquired StemSmart platform. The patented mesenchymal stromal cell (MSC) therapy has shown strong early results including a 53% remission rate in a phase II trial for refractory Crohn's disease and outperforming Humira, the long-time anti-inflammatory drug used as a standard of care. It also showed high response rates in a phase I trial for steroid-refractory Graft-versus-Host Disease (GvHD). "With the global markets for Crohn's and GvHD forecast to reach US$25 billion combined by 2035, StemSmart is tapping into significant unmet needs," O'Connell said. He also sees validation from the sector's leader Mesoblast (ASX:MSB), which recently secured US Food and Drug Administration (FDA) approval for its MSC product and now commands a $3.1bn market cap. He said by comparison, Neuroscientific trades at just ~23 cents but carries a midpoint valuation of 60 cents, representing around 161% upside based on a probability-adjusted DCF model assuming modest success rates and future partnerships. This assumes modest 20% success rates, 25% market penetration in Crohn's and potential partnerships with big pharma to fund late-stage trials. With a Special Access Program about to generate real-world data, plans to initiate Phase II trials in 18–24 months, and expansion into additional inflammatory and lung diseases, StemSmart offers a scalable pipeline. "For investors looking at the MSC space NSB could be an early-stage, high-upside opportunity positioned to follow Mesoblast's trajectory as the market matures," he said. The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Disclosure: Summit Biotech Fund held shares in Arovella, Tryptamine Therapeutics and NeuroScientific Biopharmaceuticals at the time of writing this article.